+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Iron homeostasis in relapsing steroid-sensitive nephrotic syndrome of childhood

Iron homeostasis in relapsing steroid-sensitive nephrotic syndrome of childhood

Clinical Nephrology 52(1): 25-29

Aim: Urinary transferrin loss is a typical feature in relapse of the idiopathic nephrotic syndrome, however, the impact on serum iron homeostasis and hematological parameters has not been studied systematically so far. Patients and methods: Therefore, we investigated serum iron (Fe), erythropoietin (EPO), ferritin (FN), transferrin (TF), total iron-binding capacity (TEBK), transferrin saturation and the soluble transferrin receptor (sTFR) combined with hematological parameters (hemoglobin, MCV, MCH) in 42 children with relapsing, steroid-sensitive nephrotic syndrome (NS) in remission (RM, n = 26) and relapse (RL, n = 16), including 13 patients who were studied in both states. Thirty-three age-matched healthy children served as controls. Results: Fe, TEBK and TF were significantly reduced in RL compared to RM in cross-sectional as well as in paired studies while ferritin, hematological parameters and EPO levels remained unchanged. A significant increase, however, of the soluble transferrin-receptor could be demonstrated in cross-sectional analysis comparing RL to RM and healthy controls (3568 +- 713 mg/ml vs 2625 +- 576 vs 2646 +- 697; p < 0.001 respectively) as well as in paired analysis of 13 patients in RL and RM (p < 0.001). Conclusion: We conclude that transient transferrin and iron deficiency occurs in RL of INS but this seems to be counterbalanced by upregulation of the sTFR, a mechanism that might be important in preventing the development of iron deficiency anemia during the active nephrotic state.

(PDF emailed within 1 workday: $29.90)

Accession: 010885212

Download citation: RISBibTeXText

PMID: 10442492

Related references

Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet 2(7671): 479-482, 1970

Intensive reading of steroid-sensitive, relapsing/steroid-dependent nephrotic syndrome: evidence-based guidelines on diagnosis and treatment of childhood common renal diseases (I). Zhonghua Er Ke Za Zhi 47(3): 171-172, 2011

Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Archives of Disease in Childhood 48(4): 286-290, 1973

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384(9950): 1273-1281, 2014

Controlled studies of the treatment of steroid resistant and steroid sensitive relapsing nephrotic syndrome. Alwalln , F Berglund And B Josephson (Ed ) Proceedings Of The Fourth International Congress Of Nephrology, Vol 3 Clinical Nephrology, Immunology Xi+371p S Karger: Basel, Switzerland; New York, N Y , U S A 88-91, 1970

Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology 21(1): 21-27, 2016

Seasonal variation in first episode of childhood idiopathic steroid-sensitive nephrotic syndrome and adult minimal change nephrotic syndrome. Clinical and Experimental Nephrology 19(1): 146-147, 2015

Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatric Nephrology 20(10): 1376-1381, 2005

Tubular proteinuria in steroid sensitive multi-relapsing nephrotic syndrome. Clinical Nephrology 40(1): 26-30, 1993

Immunoconglutinin and complement changes in steroid sensitive relapsing nephrotic syndrome of children. Clinical and Experimental Immunology 6(1): 109-116, 1970

Evidence-based guidelines on diagnosis and treatment of childhood common renal diseases. (I) Evidence-based guideline on diagnosis and treatment of steroid-sensitive, relapsing/steroid-dependent nephrotic syndrome (for trial implementation). Zhonghua Er Ke Za Zhi 47(3): 167-170, 2011

Mycophenolate mofetil treatment in steroid resistant/relapsing nephrotic syndrome of childhood. Journal of the American Society of Nephrology 10(PROGRAM AND ABSTR ISSUE): 111A, Sept, 1999

Frequently relapsing steroid-sensitive idiopathic nephrotic syndrome in children: Its treatment with levamisole. DMW (Deutsche Medizinische Wochenschrift) 123(9): 239-243, Feb 27, 1998

Cyclosporin A plus prednisone treatment of steroid-sensitive frequently relapsing nephrotic syndrome in children. Turkish Journal of Pediatrics 41(2): 225-230, 2000

Urinary proteome of steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome of childhood. American Journal of Nephrology 26(3): 258-267, 2006